Literature DB >> 34321323

O'Donnell-Luria-Rodan syndrome: description of a second multinational cohort and refinement of the phenotypic spectrum.

Clara Velmans1, Anne H O'Donnell-Luria2,3, Emanuela Argilli4, Frederic Tran Mau-Them5,6, Antonio Vitobello5,6, Marcus Cy Chan7, Jasmine Lee-Fong Fung7, Megan Rech8, Angela Abicht9, Marion Aubert Mucca10, Jason Carmichael11, Nicolas Chassaing10, Robin Clark12, Christine Coubes13, Anne-Sophie Denommé-Pichon5,6, John Karl de Dios14, Eleina England15, Benoit Funalot16, Marion Gerard17, Maries Joseph11, Colleen Kennedy11, Camille Kumps18, Marjolaine Willems19, Ingrid M B H van de Laar20, Coranne Aarts-Tesselaar21, Marjon van Slegtenhorst20, Daphné Lehalle16, Kathleen Leppig22, Lennart Lessmeier1, Lynn S Pais3, Heather Paterson2,23, Subhadra Ramanathan12, Lance H Rodan23,24, Andrea Superti-Furga18, Brian H Y Chung7, Elliott Sherr4, Christian Netzer1, Christian P Schaaf8,25,26, Florian Erger27.   

Abstract

BACKGROUND: O'Donnell-Luria-Rodan syndrome (ODLURO) is an autosomal-dominant neurodevelopmental disorder caused by pathogenic, mostly truncating variants in KMT2E. It was first described by O'Donnell-Luria et al in 2019 in a cohort of 38 patients. Clinical features encompass macrocephaly, mild intellectual disability (ID), autism spectrum disorder (ASD) susceptibility and seizure susceptibility.
METHODS: Affected individuals were ascertained at paediatric and genetic centres in various countries by diagnostic chromosome microarray or exome/genome sequencing. Patients were collected into a case cohort and were systematically phenotyped where possible.
RESULTS: We report 18 additional patients from 17 families with genetically confirmed ODLURO. We identified 15 different heterozygous likely pathogenic or pathogenic sequence variants (14 novel) and two partial microdeletions of KMT2E. We confirm and refine the phenotypic spectrum of the KMT2E-related neurodevelopmental disorder, especially concerning cognitive development, with rather mild ID and macrocephaly with subtle facial features in most patients. We observe a high prevalence of ASD in our cohort (41%), while seizures are present in only two patients. We extend the phenotypic spectrum by sleep disturbances.
CONCLUSION: Our study, bringing the total of known patients with ODLURO to more than 60 within 2 years of the first publication, suggests an unexpectedly high relative frequency of this syndrome worldwide. It seems likely that ODLURO, although just recently described, is among the more common single-gene aetiologies of neurodevelopmental delay and ASD. We present the second systematic case series of patients with ODLURO, further refining the mutational and phenotypic spectrum of this not-so-rare syndrome. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  behavioural; genetic counselling; genetics; human genetics; mutation

Mesh:

Year:  2021        PMID: 34321323     DOI: 10.1136/jmedgenet-2020-107470

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   5.941


  4 in total

Review 1.  The role of KMT2 gene in human tumors.

Authors:  Zhi-Long Zhang; Peng-Fei Yu; Zhi-Qiang Ling
Journal:  Histol Histopathol       Date:  2022-03-02       Impact factor: 2.303

Review 2.  Epigenetic genes and epilepsy - emerging mechanisms and clinical applications.

Authors:  Karen M J Van Loo; Gemma L Carvill; Albert J Becker; Karen Conboy; Alica M Goldman; Katja Kobow; Iscia Lopes-Cendes; Christopher A Reid; Erwin A van Vliet; David C Henshall
Journal:  Nat Rev Neurol       Date:  2022-07-20       Impact factor: 44.711

3.  O'Donnel-Luria-Rodan Syndrome: New gene variant identified in Romania (A case report).

Authors:  Andreea Cătană; Enikő Kutasi; Zina Cuzmici-Barabaș; Diana Militaru; Irina Iordănescu; Mariela Sanda Militaru
Journal:  Exp Ther Med       Date:  2022-04-04       Impact factor: 2.751

Review 4.  Genetic architecture and phenotypic landscape of deafness and onychodystrophy syndromes.

Authors:  Xue Gao; Pu Dai; Yong-Yi Yuan
Journal:  Hum Genet       Date:  2021-07-07       Impact factor: 4.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.